Fig. 2From: Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence neededThe probabilities that rivaroxaban leads to better or worse health (x-axis) than vitamin K antagonists (VKAs) in terms of Quality Adjusted Life Years (QALYs) and is more or less costly (y-axis). The figure is the result of the Monte Carlo simulation, in which the Markov model was iterated 10,000 times, whereby clinical event rates, utility scores and health care costs were randomly selected from their uncertainty distributions in each iterationBack to article page